Tumors constitute highly suppressive microenvironments in which the proliferative capacity and effector function of infiltrating T-cells are severely restricted. Co-inhibitory receptors on T-cells, such as PD-1 and CTLA-4, are key mediators of this process, and antibody blockade of these pathways restore T cell responses in mouse models of tumors, and have demonstrated clinical efficacy in cancer patients. Moreover, targeting one or more inhibitory T-cell may be necessary to optimally restore anti-tumor T cell responses. The status of tumor immunotherapies and emerging pathways that regulate tumor microenvironments will be discussed.
Network with leading experts from the scientific and clinical arenas as well as investigators in industry to discuss novel findings and developments in immunological assays and procedures. Learn about recent advances in immunotherapy, as they relate to various modalities, specific cancers, cell subsets, and animal models. Discuss Potential clinical feasibility and commercial potential of the newest data obtained from leading biomedical research laboratories.
This conference is part of the Novel Immunotherapeutics Summit 2014, which includes three additional parallel conferences shown below:12th Cytokines & Inflammation2nd Immunogenicity & ImmunotoxicityInaugural Innate Immunity
For more information, please visit http://www.gtcbio.com
GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic institutions, government organizations and the financial community.
GTC (Global Technology Community), LLC, is a privately held company founded in 2002.
| < Prev | Next > |
|---|